Med. praxi. 2014;11(5):207-209

Vascular disease in women before menopause

MUDr.Jan Piťha, CSc.
Laboratoř pro výzkum aterosklerózy, Centrum experimentální medicíny, IKEM, Praha

Atherosclerotic disease affects women to similar extent as men. Nevertheless, in women atherosclerosis develops and progresses later

in life. Regarding atherosclerotic changes and cardiovascular risk factors, women are more susceptible to smoking, diabetes mellitus and

dyslipidemia, the latter mainly represented by remnant lipoproteins; mechanisms of this increased sensitivity are not yet known. The

main reason for the differences between men and women could be female sex hormones, namely estrogens. After menopause the level

of estrogen significantly decreases and leads to an increased cardiovascular risk. However, hormone replacement therapy exerted no protective

effect to menopausal women. Therefore, recently the main approach is focused on management of traditional cardiovascular risk

factors, especially smoking, diabetes mellitus, and elevated triglycerides and optimally it should precede menopause. Similarly as in men

in women the drug of choice to correct dyslipidemias are 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors (statins), lowering

mainly LDL cholesterol, especially in the population of women with already present cardiovascular disease of atherosclerotic origin. Despite

menopause is considered as a time of acceleration of atheroslerotic changes, the latter could begin yet before reaching this point.

Keywords: women, cardiovascular disease, atherosclerosis, risk factors, gender differences

Published: September 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. Vascular disease in women before menopause. Med. praxi. 2014;11(5):207-209.
Download citation

References

  1. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-305. Go to original source... Go to PubMed...
  2. Barrett-Connor E, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991; 265: 627-631. Go to original source... Go to PubMed...
  3. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154: 229-236. Go to original source... Go to PubMed...
  4. Pappa T, Alevizaki M. Endogenous sex steroids and cardioand cerebro-vascular disease in the postmenopausal period. Eur. J. Endocrinol. 2012; 167: 145-156. Go to original source... Go to PubMed...
  5. Santoro N, Sutton-Tyrrell K. The SWAN song: Study of Women's Health Across the Nation's recurring themes. Obstet. Gynecol. Clin. North. Am. 2011; 38: 417-423. Go to original source... Go to PubMed...
  6. Cifkova R, Pitha J, Lejskova M, et al. Blood pressure around the menopause: a population Study. J. Hypertens. 2008; 26(10): 1976-1982. Go to original source... Go to PubMed...
  7. Lejsková M, Alušík S, Suchánek M, et al. Menopause: clustering of metabolic syndrome components and population changes in insulin resistance. Climacteric 2011; 14(1): 83-91. Go to original source... Go to PubMed...
  8. Vaidya D, Becker DM, Bittner V, et al. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ. 2011; 343: d5170. Go to original source... Go to PubMed...
  9. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57. Erratum in: JAMA 2002; 288(9): 1064. Go to original source... Go to PubMed...
  10. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. Go to original source... Go to PubMed...
  11. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409. Go to original source... Go to PubMed...
  12. Clarkson TB. Can women be identified that will derive considerable cardiovascular benefits from postmenopausal estrogen therapy? J. Clin. Endocrinol. Metab. 2008; 93: 37-39. Go to original source... Go to PubMed...
  13. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007; 14(3): 373-384. Go to original source... Go to PubMed...
  14. Moyer VA. U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2013; 158(1): 47-54. Go to original source... Go to PubMed...
  15. Sarrel PM, Njike VY, Vinante V, et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am. J. Public Health. 2013; 103: 1583-1588. Go to original source... Go to PubMed...
  16. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011; 124: 2145-54. Go to original source... Go to PubMed...
  17. "Your Guide To Lowering Your Blood Pressure With DASH". US Department of Health and Human Services. http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/.
  18. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010; 121: 1069-1077. Go to original source... Go to PubMed...
  19. Pitha J Králová-Lesná I, Sekerková A, et al. Menopausal transition enhances the atherogenic risk of smoking in middle aged women. Int.J. Cardiol. 2013; 168: 190-196. Go to original source... Go to PubMed...
  20. Pitha J, Auzký O, Kovář J, et al. Changes in cardiovascular risk profile in women after menopause (Prague Pre and Post Menopausal Female study), Cor et Vasa 2014; 56: e113 - e117. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.